RxDoctor Payments DataLook up a doctor →

Lawrence Davanzo, DO

Pulmonary Disease · Somerset, NJNPI 1902834708

Payments from drug & device makers

$25,964in general payments, 2019–2025

Across 1,344 payments — averaging $19.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$7K
  • GSK$5K
  • Jazz Pharmaceuticals Inc.$2K
  • Actelion Pharmaceuticals US, Inc.$2K
  • Boehringer Ingelheim$2K
  • Sanofi$1K
  • plus $8K from 36 others

What the payments were for

  • Food & beverage$24,95996%
  • Education$1,0054%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,964 in reported general payments places this provider in the 90th percentile of 472 pulmonary disease providers in New Jersey.

See all pulmonary disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$223,221
Medicare patients
394
Services billed
2,509

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate35$442,932
Trelegy ElliptaFluticasone/Umeclidin/Vilanter393$321,131
Breztri AerosphereBudesonide/Glycopyr/Formoterol211$146,735
Dupixent SyringeDupilumab19$75,884
Breo ElliptaFluticasone/Vilanterol77$41,964
BelsomraSuvorexant24$20,054
Spiriva RespimatTiotropium Bromide29$19,530
SunosiSolriamfetol Hcl17$16,179
EliquisApixaban12$9,568
Sildenafil Citrate18$7,107
Albuterol Sulfate HfaAlbuterol Sulfate262$6,991
Montelukast Sodium481$6,656
Incruse ElliptaUmeclidinium Bromide15$6,508
Fluticasone-SalmeterolFluticasone Propion/Salmeterol41$5,015
SymbicortBudesonide/Formoterol Fumarate12$4,529

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat$1,674$462,46364 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$4,997$369,603485 claims
AstraZenecaBreztri Aerosphere, Symbicort$6,591$151,263223 claims
MerckBelsomra$346$20,05424 claims
Axsome Therapeutics, Inc.Sunosi$712$16,17917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 472 pulmonary disease providers in New Jersey.

Other pulmonary disease in Somerset

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →